Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGas, bloating and burping are among the most commonly reported side effects of semaglutide, and they tend to be most noticeable in the early weeks of treatment. Semaglutide slows the rate at which food leaves the stomach, which changes the way your gut processes what you eat — and that shift in digestive pace is the main reason gas builds up. The NHS medicines page for semaglutide lists flatulence, belching and abdominal distension among the recognised side effects of Wegovy. For most people these symptoms settle as the body adjusts; they rarely mean the medicine needs to be stopped. As a prescription-only medicine, semaglutide requires clinical assessment before it can be prescribed, and a prescriber can help you weigh up how these side effects sit alongside your wider health picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone that signals fullness to the brain and slows the movement of food out of the stomach. That slowing (called delayed gastric emptying) is partly what makes the medicine effective for weight management. Food stays in your stomach longer, which helps you feel satisfied on smaller portions.
The trade-off is that a fuller, slower-moving gut creates conditions in which bacteria break down food for longer before it moves through. That fermentation produces gas. Belching, flatulence, bloating and a feeling of abdominal fullness are the results. Some people also notice nausea and reflux alongside the gas, because the same mechanism that slows the stomach can allow acid to sit higher in the digestive tract than usual.
None of this is a sign that something has gone wrong. It is a predictable physiological effect of the medicine doing what it is designed to do. The question is usually not whether it will happen, but how much it will happen and for how long. You can read more about why semaglutide causes gas in detail, including the gastric-emptying mechanism, if you want the longer explanation.
Gas symptoms follow a recognisable pattern. They are most noticeable in the first one to three weeks after starting treatment or after a dose is increased, and they usually peak a few days in before beginning to subside. This is because the digestive system is calibrating to a new pace. Most people find that by the time they have been at a given dose for three to four weeks, the worst of the bloating and burping has settled considerably.
The titration schedule (starting at a lower dose and moving up gradually over several weeks) exists partly for this reason. It gives your gut time to adapt before the dose climbs further. Whether any dose change is appropriate for you is a clinical decision, not something to adjust independently, and if you want a full overview of how semaglutide works as a treatment, that page covers the mechanism and prescribing context in detail. Your prescriber and the Patient Information Leaflet are the right guides on timing.
A small number of people find gas remains persistent beyond the initial adjustment period. If that describes your experience, it is worth raising with your clinical team rather than tolerating it quietly. There are sometimes practical adjustments (to when and how you eat) that make a significant difference, and occasionally a clinical conversation about the dose is warranted.
If you are also noticing other symptoms such as significant nausea or changes in bowel habits, the broader side-effect picture of Wegovy covers what to watch for and when to seek help.
The good news is that gas from semaglutide responds well to dietary and behavioural adjustments. These are not rigid rules, but they are the changes most people find genuinely useful.
Eat more slowly and chew thoroughly. Because food is already moving through the stomach at a reduced rate, swallowing air alongside large bites compounds the problem. Slowing down at meals reduces the amount of air entering the gut and gives digestive enzymes more time to work.
Reduce high-fat, fried or very rich foods. Fat is the hardest macronutrient to digest and sits in the stomach longest. On semaglutide, fatty meals amplify the slowed-emptying effect and tend to produce the most gas.
Watch carbonated drinks. Fizzy water, sparkling soft drinks and beer all introduce gas directly into a digestive system that is already moving slowly. Plain water is the straightforward swap, and keeping a bottle with your semaglutide pen in the fridge door makes it easy to reach for the right thing.
Keep portions smaller. The medicine is helping you feel fuller sooner, so working with that signal (stopping when comfortable rather than finishing a full plate) reduces the total fermentable load in the gut.
Move after meals. A short walk after eating supports gastric motility. Sitting still for long periods after a meal when gastric emptying is already delayed tends to worsen bloating. It is also worth knowing that other lifestyle habits can interact with treatment in unexpected ways, so if you smoke or vape it is worth reading about the effects of vaping on Wegovy before assuming it has no bearing on your side effects.
For a detailed look at the connection between semaglutide and flatulence specifically, this page on semaglutide and flatulence covers the evidence and practical management in more depth.
Mild to moderate gas is an expected part of early semaglutide treatment. There are, however, symptoms that should prompt you to seek medical attention rather than wait for natural improvement.
Severe, persistent pain in the upper or central abdomen (particularly pain that spreads to the back, and especially if accompanied by vomiting) needs prompt medical assessment. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent risk with GLP-1 medicines; the symptom profile is stomach pain that is unusually intense and does not pass quickly. This is distinct from the dull bloating and burping that most people experience.
Gallbladder symptoms (pain in the upper right abdomen, sometimes with nausea) are also worth flagging, as GLP-1 medicines have an established association with gallstones in some patients. Severe nausea or vomiting that causes dehydration should not be managed alone at home.
If you are ever unsure whether what you are experiencing is routine or needs attention, contact your prescriber. nume's clinical team offers aftercare support seven days a week, so you are never waiting until Monday morning to raise a concern. You can also report any suspected side effects through the MHRA's Yellow Card scheme.
If you are thinking about starting treatment or want to understand how semaglutide fits into the broader range of weight management options, it is worth getting the full picture first, including what to expect from semaglutide at each stage of treatment. When you are ready, speak to our prescribers to see whether Wegovy is clinically suitable for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.